drugset / Trial / NCT00401765
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate cancer.
Timeline
- Start
- 2005-09
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 9 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 12 mg/kg | Intravenous |